Cryo-Cell International, Inc.
The momentum for this stock is not very good. Cryo-Cell International, Inc. is a mediocre stock to choose.
Log in to see more information.
News
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2022
Globe Newswire OLDSMAR, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2022. Financial Results Revenue ...\n more…